Loading…
← CockpitCompetitor Analysis › 9966.HK Alphamab OncologyOpen in the cockpit ↗

Alphamab Oncology9966.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese biotech developing ADC and bispecific-antibody cancer drugs, including envafolimab, the first subcutaneous PD-L1 antibody.

Momentum laggard 16
Mkt cap
$666M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$886,153
20-day average traded
Fwd P/E
24.0×
forward earnings
ROIC−WACC
-47.6 pp
WACC 16.6%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · HKDHK$5.33
1D-2.7%
1W-13.4%
1M-24.6%
3M-34.5%
6M-37.8%
YTD-45.7%
1Y-44.4%
ATR %7.5%
52w lowhigh56.4% off high

What Alphamab Oncology does

Chinese biotech developing ADC and bispecific-antibody cancer drugs, including envafolimab, the first subcutaneous PD-L1 antibody.

Earns little from its own product sales; income comes mainly from partners that fund development and sell its drugs, through up-front fees, milestones and a share of sales. Envafolimab is commercialized in China by a partner, 3D Medicines, under a co-development deal.

Products and services

  • Envafolimab (PD-L1 antibody)
  • ADC oncology pipeline
  • Bispecific antibody pipeline

Customers

  • Hospitals/oncologists in China
  • Global licensing partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • Antibody/ADC drug discovery
  • Licensing & commercialization

What could go right

  • Envafolimab label expansion
  • Licensing/partnership deals

What could go wrong

  • Small commercial revenue base
  • Clinical trial and pricing risk

Moat: narrow (IP / patents, process know-how). Proprietary bispecific/ADC platform and a first-in-class subcutaneous PD-L1 approval, but small commercial scale.

Headquarters: Suzhou, China · Founded: 2011 · Employees: 498

Named competitors

Alphamab Oncology at a glance

Size Alphamab Oncology (9966.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $666M, the 680th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.33 on 18 Nov 2026.

Performance Over six months the shares fell 37.8%, against -13.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue fell 31.8% over the last twelve months (peer median +18.4%); the operating margin is -37.8% (peer median -92.0%).

Valuation It trades at 24.0× forward earnings against a peer median of 20.8× (2nd most expensive of 5).

Capital Return on invested capital runs 47.6 points below its cost of capital (16.6% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 879966.HK 62
Six months, rebased to 100: Alphamab Oncology against the median of its 20 peers (local-currency closes).

Alphamab Oncology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$579MHK$614MHK$694MHK$242MHK$194M
Revenue growth—-12%+187%+25%—
Gross profitHK$441MHK$475MHK$545MHK$104MHK$78.4M
EBITDA-HK$146M-HK$96.1MHK$193M-HK$281M-HK$439M
Net income-HK$194M-HK$124MHK$180M-HK$233M-HK$379M
Free cash flow-HK$193M-HK$136MHK$270M-HK$213M-HK$478M
Capital expenditureHK$17.7MHK$34.3MHK$23.6MHK$40.0MHK$151M
Total debtn/aHK$137MHK$198MHK$283MHK$388M

Quarterly statements and history in the cockpit →

Alphamab Oncology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%7729688221KURA688197301520GERNJANXATTOSRZNAURA9966.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Alphamab Oncology is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×30×GERN0028803013336886399966.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alphamab Oncology is the large dot.

Alphamab Oncology competitors and peer comparison

Head to head with its named competitors (9966.HK vs 9926.HK vs 1801.HK vs 9995.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alphamab Oncology 9966.HK$666M-38%-32%-38%24.0×n/a
Akeso 9926.HK$7.01B-48%+42%-25%n/an/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
RemeGen 9995.HK$6.07B-28%+293%61%6.3×-6.8%
Nanjing Leads Biolabs 9887.HK$764M-50%n/a-108%n/an/a

How Alphamab Oncology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alphamab Oncology against its 20 peers (data as of 18 Nov 2026)
Measure9966.HKPeer medianRank in peer set
1-month return-24.6%-7.0%3rd lowest of 21
6-month return-37.8%-13.8%3rd lowest of 19
Distance from 52-week high-56.4%-44.5%5th lowest of 21
Revenue growth (TTM)-31.8%+18.4%lowest of 15
Operating margin-37.8%-92.0%8th highest of 16
Forward P/E24.0×20.8×2nd most expensive of 5
ROIC minus cost of capital-47.6 pp-11.3 pp3rd lowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%24.0×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%n/a40.3%+21.5%
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%n/an/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%n/a44.8%+14.7%
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%19.2×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%n/an/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%37.9×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%n/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%n/a-13.5%-10.9%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a

Questions

Who are Alphamab Oncology's main competitors?
Named competitors: Akeso (9926.HK), Innovent Biologics (1801.HK), RemeGen (9995.HK), Nanjing Leads Biolabs (9887.HK). The cockpit's measured peer set (industry) also includes Steminent Biotherapeutics (7729.TWO), Frontier Biotechnologies (688221.SS), Kura Oncology (KURA), Shouyao Holdings Beijing (688197.SS), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Geron (GERN).
Is Alphamab Oncology expensive compared with its peers?
On forward p/e it trades at 24.0× against a peer median of 20.8×, 2nd most expensive of 5 in its peer set.
How has Alphamab Oncology stock performed?
Over six months to 18 Nov 2026 the shares returned -37.8% against -13.8% for the median peer; over one year -44.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.